Consistent with this, elevated METTL3 expression has been associated with more advanced tumour stage and a poorer prognosis (Yuan et al., 2020), whereas reduced METTL3 expression has been linked with advanced metastatic PCa (Cotter et al., 2021). The gene discussed is METTL3; the disease is posterior cortical atrophy.